期刊文献+

欣维宁对急性冠脉综合征患者冠状动脉介入治疗后的影响

Effect of Xinweining on Patients with Acute Coronary Syndrome Following Percutaneous Coronary Intervention
下载PDF
导出
摘要 目的:探讨替罗非班(欣维宁)对急性冠脉综合征(ACS)患者冠状动脉介入治疗(PCI)术后的影响。方法:选取入住安贞医院心内科,经冠状动脉造影确诊为ACS,并接受PCI术的患者共106例,随机分为欣维宁组和对照组,欣维宁组于PCI术后除常规外立即给予欣维宁4mL/h泵入,持续24h。对照组PCI术后常规。观察两组心绞痛发作次数,两组术前、术后即刻、24h、48h、72h血压、心率、心肌耗氧指数变化以及C反应蛋白(CRP)和氨基末端脑钠肽前体(NT-proBNP)水平。结果:两组在术前和术后即刻血压、心率并无显著差别,但术后24h欣维宁组较对照组血压、心率均有明显降低,欣维宁组:血压(122.8±16.7)mmHg/(72.5±6.7)mmHg,心率(67.4±8.5)次/分;对照组:血压(135.6±18.9)/mmHg(86.2±9.7)mmHg,心率(78.9±10.6)次/min,两组比较差别有统计学意义(P<0.01),且一直保持到术后72h,欣维宁组可有效降低心肌耗氧指数。两组在术前和术后即刻CRP、NT-proBNP并无显著差别,但术后较术前CRP、NT-proBNP水平升高,欣维宁组:术前CRP(20.4±4.3)mg/L,NT—proBNP(254.2±31.7)ng/L,术后即刻CRP(39.8±8.6)mg/L,NT-proBNP(448.9±51.2)ng/L;对照组:术前CRP(18.6±5.2)mg/L,NT-proBNP(210.5±29.8)ng/L,术后即刻CRP(41.2±9.1)mg/L,NT-proBNP(502.6±57.4)ng/L。术后24h欣维宁组较对照组CRP、NT-proBNP均有明显降低,欣维宁组:CRP(25.2±3.2)mg/L,NT-proBNP(202.5±21.4)ng/L;对照组:CRP(39.7±8.5)mg/L,NT-proBNP(482.3±49.7)ng/L,两组比较差别有统计学意义(P<0.05),且一直保持到术后72h。结论:欣维宁可降低ACS患者PCI术后的心率、血压、心肌耗氧指数,并可显著降低PCI术后CRP和NT-proBNP水平,有可能改善ACS患者PCI的预后。 Objective:To observe effects of Xinweining on patients with acute coronary syndrome following percutaneous coronary intervention.Methods: a total of 106 patients with acute coronary syndromes and underwent percutanous coronary intervention were enrolled in this report. They were randomized into the xinweining in which Xinweining was administered, 4ml/h for 24 hours, by intravenous infusion following PCI and control group. Angina pectoris, blood pressure and heart rates were recorded; all patients underwent ...
出处 《青海医药杂志》 2008年第3期12-14,共3页 Qinghai Medical Journal
关键词 急性冠脉综合征 欣维宁 冠状动脉介入治疗 Acute coronary syndromes Xinweining Percutaneous coronary intervention
  • 相关文献

参考文献5

  • 1[1]The Restore invesigators.Efflects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Circulation,1997,96:1 445~1 453.
  • 2沈杰,沈卫峰.替罗非班在急性冠脉综合征介入治疗中的应用[J].国际心血管病杂志,2006,33(3):156-159. 被引量:72
  • 3[3]The platelet receptor inhibition for ischemic syndrome management in patientshimited by unstable signs and syndrames(PRISM-PLUS) trial investigators.Inhibition of the platelet glycoprotein IIb/IIIa areceptor with tirofiban in unstabe angina and non-Q-wave myocardial infarction.N Engl J Med,1998,338:1 488~1 497.
  • 4[4]The platelet receptor inhibition for ischemic syndrome management (PRLSM) study investigators.A comparison of aspirin plus tirafiban with aspirin plus heparin for unstable angina.N Engl J Med,1998,335:1 498~1 505.
  • 5[5]Naimusbin PA,Mazwrov AV.Role of glyoprotein Iib/IIIa (ulpa Iib.beta.3 integrin) in stimulation of secretion from platelet granules.Biochemistry(Mose),2003,68(2):209~216.

二级参考文献19

  • 1[1]Elmouchi DA,Bates ER.Platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in non-ST segment elevation acute coronary syndromes[J].Minerva Cardioangiol,2003,51 (5):547-560.
  • 2[2]Valgimigli M,Percoco G,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial[J].JAMA,2005,293 (17):2109-2117.
  • 3[3]Heitzer,T Ollmann,I Koke,K et al.Platelet Glycoprotein Ⅱb/Ⅲa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease[J].Circulation,2003,108 (5):536-541.
  • 4[4]Warnholtz A,Ostad MA,Heitzer T,et al.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95 (1):20-23
  • 5[5]De Luca G,Smit JJ,Ernst N,et al.Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction[J].Thromb Haemost,2005,93 (5):820-823.
  • 6[6]Martinez-Rios MA,Rosas M,Gonzalez H,et al.Comparison of reperfusion regimens with or without tirofiban in STelevation acute myocardial infarction[J].Am J Cardiol,2004,93 (3):280-287.
  • 7[7]Lavi S,Gruberg L,Kapeliovich M,et al.The impact of GP Ⅱb/Ⅲa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients[J].J Invasive Cardiol,2005,17 (6):296-299.
  • 8[8]Roffi M,Chew DP,Mukherjee D,et al.Platelet glycoprotein Ⅱb/Ⅲa inhibition in acute coronary syndromes.Gradient of benefit related to the revascularization strategy[J].Eur Heart J,2002,23 (18):1441-1448.
  • 9[9]Sabatine MS,Morrow DA,Giugliano RP,et al.Implications of upstream glycoprotein Ⅱb/Ⅲa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction:a comparison of the Thrombolysis In Myocardial Infarction (TIMI) ⅢB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial[J].Circulation,2004,109 (7):874-880.
  • 10[10]Marsh JD.Early use of glycoprotein Ⅱb/Ⅲa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes[J].Am J Health Syst Pharm,2002,59 (21 Suppl 7):S15-S26.

共引文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部